Li, Joey H. https://orcid.org/0000-0002-3865-5876
Feng, Qinyan
Ball, Andréa B. https://orcid.org/0000-0002-8214-7190
Lee, Cassidy D.
Wallerius, Michelle L.
Bormin, Jan G.
Kapelczak, Edmund D.
Armstrong, Wesley R.
Hermans, Leen
Krall, Abigail
Matulionis, Nedas https://orcid.org/0000-0001-7624-3090
TeSlaa, Tara https://orcid.org/0000-0002-0504-0998
Christofk, Heather R. https://orcid.org/0000-0002-8662-4425
Divakaruni, Ajit S. https://orcid.org/0000-0002-2528-9651
O’Sullivan, Timothy E. https://orcid.org/0000-0003-1435-8188
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01AI174519, R01AI145997, T32GM152342, T32AI007323, F30AI181449, T32GM136614, T32GM152342, P30DK063491, 2R01CA215185, 2R01AR070245, UH2CA286583, R35GM138003, T32GM152342)
Belgian American Educational Foundation
Chan Zuckerberg Initiative
Agilent Technologies (4814)
W. M. Keck Foundation (995337)
Article History
Received: 17 January 2025
Accepted: 7 July 2025
First Online: 14 August 2025
Competing interests
: T.E.O. is a scientific advisor for Modulus Therapeutics and Xyphos Biosciences, companies that have a financial interest in human NK cell-based therapeutics. The other authors declare no competing interests.